SOHO
The effect of GLP1 receptor agonists in hand osteoarthritis and overweight/obesity
Project manager
Postdoctoral fellow
ABOUT THE PROJECT
This is a double-blind, randomized, placebo-controlled study where eligible participants with hand osteoarthritis and overweight/obesity will be randomly assigned to either a GLP1 receptor agonist or placebo.
Eligible participants are people with hand osteoarthritis, hand pain, and overweight/obesity. Participants will be treated for one year.
Our primary endpoint is change in hand pain at one year. Participants will be followed for one year after the end of the study to study changes in symptoms and body composition.
WHO CAN JOIN?
Adult men and women with osteoarthritis of the hands according to the EULAR classification criteria, pain in the hands (at least 40 on a 0-100 scale) and overweight/obesity. Individuals with other arthritic diseases, recent hand surgery or recent use of systemic corticosteroids, injections into joints/tendons in the hand or GLP1 receptor agonists will be excluded.
WHAT DOES THE STUDY INVOLVE?
Participants will attend five visits (inclusion, weeks 8, 20, 36 and 52) following a screening examination. After completing treatment, participants will be followed up at weeks 26 and 52. The treatment and follow-up are at no cost to the participants.
Full English title: The efficacy and safety of a GLP-1 receptor agonist in patients with painful hand osteoarthritis and overweight/obesity